Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lazabemide
- Development stage
- Discontinued
- Lead developer
- Roche
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Lazabemide is a **reversible and selective inhibitor of monoamine oxidase B (MAO-B)**, developed as an antiparkinsonian agent. Unlike selegiline, lazabemide is not metabolized to active compounds or amphetamines. By inhibiting MAO-B, lazabemide prevents the breakdown of dopamine, increasing its availability in the brain, which is relevant for the treatment of Parkinson's disease. Lazabemide was specifically investigated for **delaying the need for levodopa therapy in early, untreated Parkinson's disease**. Clinical studies indicated its efficacy in delaying disability progression and showed good tolerability. The drug was never marketed and is considered an abandoned development project[6][8][3][5][1][7][9].
- Brand names
- PakioTempium
- Other names
- lazabemide hydrochloride
02
Targets
MAOB (Monoamine oxidase B)MAOA (Monoamine oxidase A)
Beyond the preview
Go deeper on lazabemide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lazabemide.